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Spectral karyotyping (SKY) enables the visualization of all 24 
human chromosomes assigned in different colours in a single 
metaphase, by using a combination of probe labelling, 
fluorescence microscopy, spectroscopy, CCD-imaging and 
spectral image analysis. The benefits of such an approach 
include the accurate analysis of abnormal karyotypes, 
unresolved by conventional cytogenetics and the ability to 
identify cryptic translocations in apparently 'normal' karyotypes. 
The labelling procedure is based on the utilization of five 
fluorochromes, differently combined for each specific 
chromosome. The SKY system (microscope and acquisition 
software) receives and processes the emitted signals, assigning 
a specific colour to a specific chromosome. In this image, the 
karyotype of a male affected by acute myeloid leukaemia is 
represented, showing the presence of the following 
rearrangements: del1q, balanced t(4;11) and balanced t(5;9). 
[Realized with the collaboration of Dr Idoya Lahortiga, visiting 
our institute in 2001.] 
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